Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q2 2018 · 10-Q
Revenue$7.37M$7.37M+138.0% vs Q2 2017 Net Income-$38.72M-$38.72MN/M vs Q2 2017 EPS Diluted-$0.82-$0.82N/M vs Q2 2017 Operating Income-$39,657,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$18,123,000N/M Margins · derivedOperating margin-537.9%+305.3 pt vs Q2 2017
Net margin-525.3%+328.4 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 7, 2018 · 38 d after period end